DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221)
CAT#: VS-1224-YC221
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for T-cell-driven autoimmune diseases, aiming at treating psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders. The DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221) is an anti-drug antibody (ADA) against Briakinumab. This drug-based antibody is raised in mice immunized with the Briakinumab. The anti-Briakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Briakinumab in samples.
Specifications
- Host Animal
- Mouse
- Specificity
- Briakinumab
- Target
- Briakinumab
- Immunogen
- Briakinumab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Briakinumab
- Drug Weight
- 146500.0 Da
- Formula
- C₆₃₇₆H₉₈₇₄N₁₇₂₂O₁₉₉₂S₄₄
- Related Disease
- psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for VS-1224-YC221. Click the button above to contact us or submit your feedback about this product.
Specific Anti IL-12 Antibody Detector
We are studying autoimmune diseases and needed a way to measure Briakinumab levels. This mouse antibody was highly specific for the human monoclonal drug, enabling us to conduct detailed ELISA assays to assess its pharmacokinetic behavior in our models.
Trustworthy Standard For ADA Assays
Establishing a reliable ADA assay for Briakinumab was made easier with this product. It acts as a perfect reference standard, allowing us to calibrate our assays effectively and ensure consistent monitoring of potential immunogenicity in our research samples.
Q&As
-
What does Briakinumab target, and what is this antibody's specificity?
A: Briakinumab is a human monoclonal antibody that targets the proinflammatory cytokine IL-12. Our DrugMonitor™ Anti-Briakinumab Antibody is an anti-drug antibody (ADA) raised in mice specifically against Briakinumab, ensuring high specificity for this therapeutic agent.
-
What are the storage instructions for this antibody?
A: You should store the antibody at 4°C for immediate use within one to two weeks. For long-term storage up to one year, please keep it at -20°C. It is important to avoid repeated freezing and thawing to maintain the antibody's activity.
View the frequently asked questions answered by Creative Biolabs Support.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Briakinumab"
Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab)Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-103)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. It is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like , the antibody targets the interleukins 12 and 23.
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: WB, IF, IP, Neut, FuncS, ELISA, FC
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, Neut, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
